If he becomes chairman, Cummings said, he would take a fresh look at which of the 64 subpoenas he would still like to see issued, and what new areas he might explore. He said his agenda would likely include probing the administration's prescription drug policies. A plan laid out by Trump in May relies on increasing market competition and reducing regulatory constraints so drugs can get to market faster and less expensively. The plan did not include direct negotiations by Medicare to lower prices for seniors, a strategy long embraced by Democrats and by Trump during the campaign.